Selected article for: "cohort study and SARS patient"
Author: Başaran, Seniha; Şimşek-Yavuz, Serap; Meşe, Sevim; Çağatay, Atahan; Medetalibeyoğlu, Alpay; Öncül, Oral; Özsüt, Halit; Ağaçfidan, Ali; Gül, Ahmet; Eraksoy, Haluk
Title: The effect of tocilizumab, anakinra, and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response
  • Cord-id: dplcwwps
  • Document date: 2021_3_15
    • ID: dplcwwps
    Snippet: OBJECTIVES: Disease severity, previous medications, immunosuppresive agents could affect the antibody response against SARS-CoV-2. We aimed to analyze variables affecting the humoral response to SARS-CoV-2. METHODS: In this prospective cohort study, we included adult patients who recovered from COVID-19 and were admitted to COVID-19 follow-up unit. We defined 8 patient groups in accordance with the results of thorax CT, SARS-CoV-2 PCR test, and tocilizumab or anakinra use during active disease.
    Document: OBJECTIVES: Disease severity, previous medications, immunosuppresive agents could affect the antibody response against SARS-CoV-2. We aimed to analyze variables affecting the humoral response to SARS-CoV-2. METHODS: In this prospective cohort study, we included adult patients who recovered from COVID-19 and were admitted to COVID-19 follow-up unit. We defined 8 patient groups in accordance with the results of thorax CT, SARS-CoV-2 PCR test, and tocilizumab or anakinra use during active disease. Anti-S IgG antibodies were determined by ELISA in serum samples. Anti-S positive and negative cases were compared. RESULTS: A total of 518 patients were included in the study. SARS-CoV-2 IgG antibodies were positive in 82.8% of patients. SARS-CoV-2 PCR positivity, extent of lung involvement on CT, and time to antibody testing were independently associated with antibody positivity. Tocilizumab, anakinra or prednisolone use was not a factor affecting the antibody response. The rate of antibody response and sample/CO values among antibody positive patients showed a linear relationship with the extent of lung involvement on CT. CONCLUSIONS: The use of tocilizumab, anakinra, and prednisolone for COVID-19 did not affect the antibody response against SARS-CoV-2. The main driver of antibody response among patients with COVID-19 was the extent of pulmonary involvement on CT.

    Search related documents:
    Co phrase search for related documents
    • active phase and logistic regression analysis: 1
    • active phase and lymphocyte neutrophil: 1
    • activity tocilizumab and logistic regression: 1, 2
    • activity tocilizumab and logistic regression analysis: 1
    • activity tocilizumab and lymphocyte neutrophil: 1
    • acute change and logistic regression: 1, 2, 3
    • acute change and logistic regression analysis: 1
    • acute change and lung involvement: 1
    • acute change and lymphocyte count: 1
    • acute change and lymphocyte neutrophil: 1
    • acute onset and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute onset and logistic regression analysis: 1, 2
    • acute onset and long duration: 1
    • acute onset and lung involvement: 1, 2
    • acute onset and lymphocyte count: 1, 2, 3, 4
    • acute onset and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6
    • admission laboratory test and logistic regression: 1, 2, 3
    • admission laboratory test and lymphocyte count: 1, 2, 3
    • admission laboratory test and lymphocyte neutrophil: 1, 2, 3